Axsome Therapeutics IncAXSM

Capital at risk.

About Axsome Therapeutics Inc
Ticker
info
AXSM
Trading on
info
NASDAQ
ISIN
info
US05464T1043
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Herriot Tabuteau M.D.
Headquarters
info
One World Trade Center, New York, NY, United States, 10007
Employees
info
683
Website
info
axsome.com
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Metrics
BasicAdvanced
Market cap
info
$6.07B
P/E ratio
info
-
EPS
info
-$5.98
Dividend Yield
info
0.00%
Beta
info
1
Forward P/E ratio
info
0
EBIDTA
info
$-244M
Ex dividend date
info
-
Price & volume
Market cap
info
$6.07B
Average daily volume
info
1.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
15.73
Price to book
info
106.41
Earnings
EPS
info
-$5.98
EPS estimate (current quarter)
info
-$1.00
EPS estimate (next quarter)
info
-$0.98
EBITDA
info
$-244M
Revenues (TTM)
info
$386M
Revenues per share (TTM)
info
$8.05
Technicals
Beta
info
1
52-week High
info
$139.13
52-week Low
info
$64.11
50-day moving average
info
$106.62
200-day moving average
info
$91.85
Short ratio
info
5.25
Short %
info
14.39%
Management effectiveness
ROE (TTM)
info
231.63%
ROA (TTM)
info
27.28%
Profit margin
info
74.47%
Gross profit margin
info
$352M
Operating margin
info
51.89%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
66.00%
Share stats
Outstanding Shares
info
48.8M
Float
info
36.7M
Insiders %
info
16.95%
Institutions %
info
77.71%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 17 analysts.

Average price target

info
$173.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.44
-$1.20
20.00%
Q1 • 24Beat
-$1.67
-$1.33
25.56%
Q2 • 24Beat
-$1.34
-$1.41
4.83%
Q3 • 24Beat
-$1.54
-$1.00
53.60%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$105M
$-64.6M
61.67%
Q3 • 24
$119M
$-74.9M
63.08%
Q4 • 24
13.37%
15.96%
2.29%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$561M
$469M
83.45%
Q3 • 24
$568M
$511M
89.97%
Q4 • 24
1.25%
9.16%
7.81%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-18.6M
$-0.1M
$30.4M
$-18.5M
Q3 • 24
$-26.2M
$-0M
$14.2M
$-26.2M
Q4 • 24
40.64%
66.67%
53.15%
41.94%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Extreme greed

+1.5

0.88

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Axsome Therapeutics Inc share?
Collapse

Axsome Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Axsome Therapeutics Inc have?
Collapse

Axsome Therapeutics Inc currently has 48.8M shares.

Does Axsome Therapeutics Inc pay dividends?
Collapse

No, Axsome Therapeutics Inc doesn't pay dividends.

What is Axsome Therapeutics Inc 52 week high?
Collapse

Axsome Therapeutics Inc 52 week high is $139.13.

What is Axsome Therapeutics Inc 52 week low?
Collapse

Axsome Therapeutics Inc 52 week low is $64.11.

What is the 200-day moving average of Axsome Therapeutics Inc?
Collapse

Axsome Therapeutics Inc 200-day moving average is $91.85.

Who is Axsome Therapeutics Inc CEO?
Collapse

The CEO of Axsome Therapeutics Inc is Dr. Herriot Tabuteau M.D..

How many employees Axsome Therapeutics Inc has?
Collapse

Axsome Therapeutics Inc has 683 employees.

What is the market cap of Axsome Therapeutics Inc?
Collapse

The market cap of Axsome Therapeutics Inc is $6.07B.

What is the P/E of Axsome Therapeutics Inc?
Collapse

The current P/E of Axsome Therapeutics Inc is null.

What is the EPS of Axsome Therapeutics Inc?
Collapse

The EPS of Axsome Therapeutics Inc is -$5.98.

What is the PEG Ratio of Axsome Therapeutics Inc?
Collapse

The PEG Ratio of Axsome Therapeutics Inc is 0.

What do analysts say about Axsome Therapeutics Inc?
Collapse

According to the analysts Axsome Therapeutics Inc is considered a buy.